Search results for "prognostic"

showing 10 items of 316 documents

International consensus guidelines for scoring the histopathological growth patterns of liver metastasis

2017

BACKGROUND: Liver metastases present with distinct histopathological growth patterns (HGPs), including the desmoplastic, pushing and replacement HGPs and two rarer HGPs. The HGPs are defined owing to the distinct interface between the cancer cells and the adjacent normal liver parenchyma that is present in each pattern and can be scored from standard haematoxylin-and-eosin-stained (H&E) tissue sections. The current study provides consensus guidelines for scoring these HGPs.METHODS: Guidelines for defining the HGPs were established by a large international team. To assess the validity of these guidelines, 12 independent observers scored a set of 159 liver metastases and interobserver var…

0301 basic medicineOncologycongenital hereditary and neonatal diseases and abnormalitiesCancer Researchmedicine.medical_specialtyPathologyIntraclass correlationmedicine.medical_treatmentcolorectal cancerGuidelineMetastasisangiogenesis03 medical and health sciencesbreast cancer0302 clinical medicineSDG 3 - Good Health and Well-beingInternal medicineJournal ArticlemedicineHumansNeoplasm Metastasisprognostic factorintegumentary systembusiness.industryLiver Neoplasmsnutritional and metabolic diseasesvessel co-optionGold standard (test)medicine.diseaseliver metastasis030104 developmental biologyTissue sectionsPractice GuidelineOncology030220 oncology & carcinogenesisCancer cellCohortBiomarker (medicine)Hepatectomytumour microenvironmentbusinessBritish Journal of Cancer
researchProduct

Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis.

2016

Clinical trials investigated the potential role of both KRAS and BRAF mutations, as prognostic biomarkers, in colorectal cancer (CRC) patients who underwent surgical treatment of CRC-related liver metastases (CLM), showing conflicting results. This meta-analysis aims to review all the studies reporting survival outcomes (recurrence free survival (RFS), and/or overall survival (OS)) of patients undergoing resection of CLM, stratified according to KRAS and/or BRAF mutation status. Background: Clinical trials investigated the potential role of both KRAS and BRAF mutations, as prognostic biomarkers, in colorectal cancer (CRC) patients who underwent surgical treatment of CRC-related liver metast…

0301 basic medicineOncologyendocrine system diseasesColorectal cancerLiver metastasimedicine.medical_treatmentColorectal Neoplasmmedicine.disease_cause0302 clinical medicineLiver metastasisHematologyTumorLiver NeoplasmsHematologyPrognosisSurvival RateOncologyLiver Neoplasm030220 oncology & carcinogenesisMeta-analysisKRASColorectal NeoplasmsHumanProto-Oncogene Proteins B-rafmedicine.medical_specialtyPrognostic biomarkerPrognosiResectionBRAFProto-Oncogene Proteins p21(ras)03 medical and health sciencesInternal medicineBRAF; Colorectal cancer; KRAS; Liver metastasis; Prognostic biomarker; Biomarkers Tumor; Colorectal Neoplasms; Humans; Liver Neoplasms; Mutation; Prognosis; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Survival Rate; Hepatectomy; Oncology; Hematology; Geriatrics and GerontologymedicineKRASBiomarkers TumorHepatectomyHumansneoplasmsSurvival ratebusiness.industrymedicine.diseaseColorectal cancerdigestive system diseasesClinical trial030104 developmental biologyMutationBRAF; Colorectal cancer; KRAS; Liver metastasis; Prognostic biomarker; Biomarkers; Tumor; Colorectal Neoplasms; Humans; Liver Neoplasms; Mutation; Prognosis; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Survival Rate; Hepatectomy; Oncology; Hematology; Geriatrics and GerontologyHepatectomyGeriatrics and GerontologybusinessBiomarkersCritical reviews in oncology/hematology
researchProduct

The liquid biopsy in the management of colorectal cancer patients: Current applications and future scenarios.

2018

The term liquid biopsy refers to the analysis of biomarkers in any body fluid, including blood, urine and cerebrospinal fluid. In cancer, liquid biopsy testing allows the analysis of tumor-derived DNA, RNA, miRNA and proteins that can be either cell-free or contained in circulating tumor cells (CTC), extracellular vesicles (EVs) or platelets. A number of studies suggest that liquid biopsy testing could have a relevant role in the management of colorectal cancer (CRC) patients at different stages of the disease. Analysis of cell-free DNA (cfDNA), CTC and/or miRNA can provide relevant information for the early diagnosis of CRC and the identification of minimal residual disease and, more gener…

0301 basic medicineOncologymedicine.medical_specialtyColorectal cancerDiseaseColorectal NeoplasmPredictivePrognosticSomatic evolution in cancer03 medical and health sciences0302 clinical medicineCirculating tumor cellInternal medicinemedicineCell-Free Nucleic AcidBiomarkers TumorHumansRadiology Nuclear Medicine and imagingLiquid biopsybusiness.industryLiquid BiopsyCancerDisease ManagementGeneral MedicineBiomarkerDNA Neoplasmmedicine.diseaseMinimal residual disease3. Good healthColorectal carcinoma030104 developmental biologyOncology030220 oncology & carcinogenesisBiomarker (medicine)businessColorectal NeoplasmsCell-Free Nucleic AcidsHumanCancer treatment reviews
researchProduct

Significance of the prognostic stratification of extranodal extension in colorectal cancer

2016

0301 basic medicineOncologymedicine.medical_specialtyLymphatic metastasisbusiness.industryColorectal cancerExtranodal Extensionextranodal extensioncolorectal cancerHematologymedicine.diseasePrognostic stratification03 medical and health sciences030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicineMedicinebusinessAnnals of Oncology
researchProduct

Arginase 1 Is a Marker of Myeloid-Mediated Immunosuppression with Prognostic Meaning in Classic Hodgkin Lymphoma

2016

Abstract Purpose : Neutrophilia is hallmark of classic Hodgkin Lymphoma (cHL), but its precise characterization remains elusive. We aimed at investigating the immunosuppressive role of high-density neutrophils in HL. Experimental design : First, N-HL function was evaluated in vitro, showing increased arginase (Arg-1) expression and activity compared to healthy subjects. Second, we measured serum level of Arg-1 (s-Arg-1) by ELISA in two independent, training (N=40) and validation (N=78) sets. Results : s-Arg-1 was higher in patients with advanced stage (p=0.045), B-symptoms (p=0.0048) and a positive FDG-PET scan after two cycles of chemotherapy (PET-2, p=0.012). Baseline levels of s-Arg-1 &g…

0301 basic medicineOncologymedicine.medical_specialtyPrognostic variableMyeloidmedicine.medical_treatmentImmunologyBiochemistry03 medical and health sciencesInternal medicinemedicineProgression-free survivalChemotherapybusiness.industryImmunosuppressionCell BiologyHematologymedicine.diseaseChemotherapy regimenNeutrophiliaLeukemia030104 developmental biologymedicine.anatomical_structureImmunologymedicine.symptombusinessBlood
researchProduct

Prognostic Significance of Survivin Expression in Patients with Ovarian Carcinoma: A Meta-Analysis

2021

Background: Survivin belongs to the protein family of inhibitors of apoptosis (IAP) and is a regulator of the cell cycle and apoptosis. The aim of this study was to assess the clinical and prognostic significance of expression survivin in patients with ovarian cancer. Methods: We systematically searched for articles in PubMed, the American Chemical Society (Publications), Medline, the Royal Society of Chemistry, Scopus and the Web of Science. Patient clinical data, overall survival (OS), disease-free survival (DFS), and survivin expression were extracted from individual studies. We performed statistical analysis using the STATA 16 package. Eighteen publications containing data from 2233 pat…

0301 basic medicineOncologymedicine.medical_specialtylcsh:MedicineReviewsurvivin03 medical and health sciences0302 clinical medicineInternal medicineOvarian carcinomaSurvivinmedicineprognostic factorProspective cohort studybusiness.industrylcsh:RGeneral MedicineOdds ratiomedicine.diseasemeta-analysisovarian cancer030104 developmental biology030220 oncology & carcinogenesisRelative riskMeta-analysisBiomarker (medicine)Ovarian cancerbusinessJournal of Clinical Medicine
researchProduct

Increased liver carcinogenesis and enrichment of stem cell properties in livers of Dickkopf 2 (Dkk2) deleted mice.

2013

// Thorsten Maass 1 , Jens Marquardt 2 , Ju-Seog Lee 3 , Markus Krupp 4 , Peter Scholz-Kreisel 2 , Carolin Mogler 5 , Peter Schirmacher 5 , Martina Muller 1 , Heiner Westphal 6 , Peter R. Galle 2 , Andreas Teufel 1 1 Department of Internal Medicine I, University of Regensburg, Regensburg, Germany 2 I. Department of Medicine, University Medical Center Mainz, Mainz, Germany 3 Cancer Biology Program, MD Anderson Cancer Center, Houston, TX, USA 4 Department of Informatics, Johannes Gutenberg University Mainz, Mainz, Germany 5 Institute of Pathology, University of Heidelberg, Heidelberg, Germany 6 Laboratory of Mammalian Genes and Development, National Institute of Child Health and Human Develop…

0301 basic medicinePathologymedicine.medical_specialtyCarcinogenesisBiologymedicine.disease_causeTranscriptome03 medical and health sciencesMicestem cellsmedicineAtypiaAnimalsHumansGene Regulatory Networksprognostic signatureGeneWnt Signaling PathwayMice Knockouttranscriptomics profilingLiver CarcinogenesisDkk2Liver NeoplasmsGastroenterologyWnt signaling pathwaymedicine.diseaseMolecular biologyMice Inbred C57BL030104 developmental biologymedicine.anatomical_structureOncologyHepatocyteCancer researchNeoplastic Stem CellsIntercellular Signaling Peptides and ProteinsStem cellLiver cancerCarcinogenesisgenetic signatureResearch PaperOncotarget
researchProduct

Neuroendocrine differentiation in a large series of genetically-confirmed Ewing’s sarcoma family tumor: Does it provide any diagnostic or prognostic …

2021

Given the potential for neuroendocrine differentiation in Ewing's sarcoma family of tumors (ESFT), we aimed to determine neuroendocrine expression in a large series of genetically-confirmed ESFT and its prognostic significance in clinically-localised neoplasms (n = 176). Slides prepared from tissue microarrays were stained for Insulinoma-associated protein 1 (INSM1), CD56, chromogranin-A and synaptophysin. INSM1 expression was present in 59% of ESFT, while synaptophysin, chromogranin-A and CD56 were expressed in only 13%, 8% and 5% of ESFT, respectively. Histological subtypes were only significantly correlated with INSM1 (p = 0.032) or CD56 (p = 0.016) immunoexpression. Regarding prognosis,…

0301 basic medicinePrognostic factorLung NeoplasmsSynaptophysinSarcoma EwingNeuroendocrine differentiationPathology and Forensic Medicine03 medical and health sciences0302 clinical medicineBiomarkers TumormedicineHumansTissue microarraybiologybusiness.industryEwing's sarcomaLarge seriesChromogranin ACell DifferentiationCell Biologymedicine.diseaseCarcinoma NeuroendocrineRepressor Proteins030104 developmental biology030220 oncology & carcinogenesisSynaptophysinbiology.proteinCancer researchSarcomabusinessPathology - Research and Practice
researchProduct

Genome-Wide DNA Methylation Profiling in Early Stage I Lung Adenocarcinoma Reveals Predictive Aberrant Methylation in the Promoter Region of the Long…

2020

Introduction: Surgical procedure is the treatment of choice in early stage I lung adenocarcinoma. However, a considerable number of patients experience recurrence within the first 2 years after complete resection. Suitable prognostic biomarkers that identify patients at high risk of recurrence (who may probably benefit from adjuvant treatment) are still not available. This study aimed at identifying methylation markers for early recurrence that may become important tools for the development of new treatment modalities. Methods: Genome-wide DNA methylation profiling was performed on 30 stage I lung adenocarcinomas, comparing 14 patients with early metastatic recurrence with 16 patients with …

0301 basic medicinePulmonary and Respiratory MedicineOncologyLung adenocarcinomamedicine.medical_specialtyLung NeoplasmsADNAdenocarcinoma of LungMethylation profilingmedicine.disease_causeMethylation03 medical and health sciences0302 clinical medicinePrognostic markerPLUTInternal medicineBiomarkers TumorHumansMedicineddc:610Promoter Regions Geneticbusiness.industryHazard ratioPromoterMethylationDNADNA MethylationPrognosismedicine.diseaseLong non-coding RNA030104 developmental biologyDifferentially methylated regionsOncology030220 oncology & carcinogenesisIncRNACàncer de pulmóBiomarker (medicine)AdenocarcinomaRNA Long NoncodingNeoplasm Recurrence LocalLung cancerbusinessCarcinogenesisMetilació
researchProduct

The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classificatio…

2016

AbstractThe IASLC Staging and Prognostic Factors Committee has collected a new database of 94,708 cases donated from 35 sources in 16 countries around the globe. This has now been analysed by our statistical partners at Cancer Research And Biostatistics and, in close collaboration with the members of the committee proposals have been developed for the T, N, and M categories of the 8th edition of the TNM Classification for lung cancer due to be published late 2016. In this publication we describe the methods used to evaluate the resultant Stage groupings and the proposals put forward for the 8th edition.

0301 basic medicinePulmonary and Respiratory Medicinemedicine.medical_specialtyPathologyLung NeoplasmsStagingMedizinPrognostic factors1102 Cardiovascular Medicine And HaematologyLung cancer; Prognostic factors; Staging03 medical and health sciences0302 clinical medicineSeer programmedicineHumansOncology & CarcinogenesisStage (cooking)Lung cancerNeoplasm Stagingbusiness.industryGeneral surgeryInternational Association for the Study of Lung Cancer Staging and Prognostic Factors Committee Advisory Boards and Participating Institutions1103 Clinical SciencesPrognosismedicine.diseaseInternational Association for the Study of Lung Cancer Staging and Prognostic Factors Committee Advisory Boards and Participating Institutions030104 developmental biologyOncology030220 oncology & carcinogenesisNeoplasm stagingBiostatisticsLung cancer stagingLung cancerbusinessSEER Program
researchProduct